Non-Hodgkin lymphoma

Researchers are testing a cell therapy made from healthy donor immune cells that are gene edited with CRISPR-Cas9 and engineered to target CD19, a marker on B-cell lymphomas. The trial enrolls about 30 adults with relapsed or refractory B-cell non-Hodgkin's lymphoma. Phase 1 chec…

Researchers are testing a personalized cell therapy called MT-601 in adults with Hodgkin or non-Hodgkin lymphoma that has come back or stopped responding to treatment. MT-601 is made from each participant's own T cells, which are trained in the lab to recognize several targets fo…

This study compares three different flu vaccines in 60 adults with blood cancers like leukemia or lymphoma. The goal is to see which vaccine triggers the strongest immune response in people with weakened immune systems. Participants will receive one of the vaccines and have their…

This Phase 2 trial is testing a new drug called MEN1703, both alone and combined with another drug called glofitamab, in 178 adults with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The study aims to see if the drugs…

This study tests an experimental immunotherapy called MK-1045 in 200 people with two types of non-Hodgkin lymphoma: follicular lymphoma (slow-growing) and diffuse large B-cell lymphoma (fast-growing). Participants have already tried at least two other treatments without success. …

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…

This phase 2 trial is testing whether adding the drug acalabrutinib to standard chemotherapy and rituximab can improve cure rates for people with untreated diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma. About 132 adults with aggressive B-cell lymphom…

This early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…

This study tests whether adding the drug ibrutinib to standard chemotherapy can better control primary central nervous system lymphoma (PCNSL) in people who are not eligible for a stem cell transplant. About 30 adults aged 65 or older or with other health issues will receive the …

This phase 3 trial is testing a CAR-T cell therapy called tisagenlecleucel that didn't quite meet commercial release standards. It's for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma who have no other approved options. The study will check if th…

This study tests a new drug called AZD3470, alone or with pembrolizumab (Keytruda), in people with certain blood cancers like lymphoma. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 161 adults and teens will take part.

This study tests a new drug called BMS-986458, which works by breaking down a protein that helps lymphoma cells grow. It is being tested alone or with other lymphoma drugs in people whose non-Hodgkin lymphoma has returned or not responded to prior treatments. The trial aims to fi…

This Phase 2 trial is testing an investigational drug called surovatamig (AZD0486) in adults with relapsed or refractory B-cell non-Hodgkin lymphoma, including follicular lymphoma and large B-cell lymphoma. Participants must have tried at least two prior treatments. The study aim…

This study tests a standardized, optimized approach to cord blood transplantation for adults with high-risk blood cancers like leukemia and lymphoma. The method includes specific chemotherapy, radiation, and stem cell dosing, followed by careful monitoring. Researchers hope to im…

This study tests a new drug combination (glofitamab plus gemcitabine and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a better steroid plan can reduce a serious side effect called …

This study tests a new oral drug, BGB-16673, designed to destroy a protein called BTK that helps certain blood cancers grow. The trial includes about 645 people with various B-cell cancers (like lymphoma and leukemia) that have come back or not responded to prior treatments. The …

This early-stage trial is testing a new drug called JNJ-95566692, a trispecific antibody designed to target lymphoma cells. It is given alone or with another drug (JNJ-87801493) to about 130 people whose B-cell non-Hodgkin lymphoma has not responded to or returned after at least …

This phase 2 trial tests a drug called PTX-100 in 115 adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Participants receive PTX-100 by IV infusion over several cycles. The goal is to see if the drug can shrink or eliminate tumors an…

This study tests a drug called IgPro20 in 63 adults who have a weakened immune system after receiving CAR T-cell therapy for blood cancers like lymphoma or multiple myeloma. The goal is to see if the drug can lower the number of serious bacterial infections, such as pneumonia or …

This trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…

Researchers are testing a chemotherapy regimen called CMOP±R in adults newly diagnosed with non-Hodgkin's lymphoma. The regimen combines liposomal mitoxantrone with cyclophosphamide, vincristine, prednisone, and optional rituximab, given in four-week cycles. The study aims to mea…

This early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …

This early-phase trial is testing a new type of CAR T cell therapy called Azer-cel, which is made from healthy donor cells rather than the patient's own cells. It aims to treat adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and relat…

This study is testing a new experimental drug called LY4584180 in adults with certain types of blood cancer (like lymphoma) that have not improved after at least two prior treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shr…

This early-stage trial tests a new drug called LY4152199 in about 215 adults with certain types of blood cancer (like follicular lymphoma or diffuse large B-cell lymphoma) that have already been treated. The drug is designed to help the body's immune cells attack the cancer. The …

This early-stage trial is testing a new drug called TLN-121, alone or with other medicines, in about 180 people whose Non-Hodgkin Lymphoma has returned or stopped responding to prior treatments. The main goals are to check the drug's safety and how the body processes it, while al…

This early-stage trial tests an experimental drug called ARV-393 in 255 adults with advanced non-Hodgkin's lymphoma that has come back or not responded to other treatments. The drug is taken as a pill and works by breaking down a protein that helps lymphoma grow. The main goals a…

The TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…

This study tests a new drug called AZD4512, alone or with other cancer medicines, in adults with relapsed or refractory B-cell Non-Hodgkin lymphoma (a type of blood cancer). The goal is to find safe doses and check if the drug shrinks tumors. About 91 participants will take part …

This study tests a new drug called GNC-035 in 40 adults with non-Hodgkin lymphoma that has returned or not improved after standard therapy. The drug is a tetra-specific antibody designed to attack cancer cells in multiple ways. The goal is to find a safe dose and see if it can sh…

This study tests a new drug called GNC-038, a tetra-specific antibody designed to target cancer cells in people with Non-Hodgkin's lymphoma that has come back or not responded to treatment. About 40 adults will receive the drug by IV to see if it is safe and can shrink tumors. Th…

This early-phase study tests a new type of CAR-T cell therapy for people with certain blood cancers (like leukemia and lymphoma) that have not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack cancer cells. The main goa…

This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Epcoritamab helps immune cells attack lymphoma cells, while ibrutinib blocks signals that help cancer ce…

This early-stage trial tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have aggressive B-cell non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of…

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This study tests a new treatment called rondecabtagene autoleucel (ronde-cel) for people with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. Ronde-cel is a CAR T-cell therapy that targets two proteins (CD19 and CD20) on cancer cells. …

This phase 2 trial tests the drug daratumumab in 28 adults with three rare and aggressive blood cancers: primary effusion lymphoma, plasmablastic lymphoma, and multicentric Castleman disease. Participants must have failed standard therapy or be unable to receive it. Daratumumab i…

This study tests a new drug called BGB-16673 for people in China with certain blood cancers (B-cell malignancies) that have come back or not responded to treatment. The drug works by breaking down a protein that helps cancer cells grow. The trial has two parts: first, finding the…

This phase 2 study tests an oral drug called nemtabrutinib in about 490 people with blood cancers like chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenstrom's macroglobulinemia. The goal is to see if the drug can shrink tumors and control the cancer, while also chec…

This study tests whether low-intensity mechanical stimulation (LIMS) vibration therapy can help blood cancer patients who are about to receive a stem cell transplant or cell therapy. The vibration board sends gentle waves through the bones, which may stimulate bone growth, improv…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This early-stage study tests a new treatment called UB-VV111 given with rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The main goal is to check the saf…

This study tests whether a newer drug called pirtobrutinib works better than the current standard drug ibrutinib for people with chronic lymphocytic leukemia or small lymphocytic lymphoma. About 737 adults who need treatment for their cancer will be randomly assigned to receive o…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This early-phase trial is testing a new type of immunotherapy for people with T-cell leukemia or lymphoma that has returned. The treatment involves taking a patient's own immune cells (or cells from a past stem cell donor), adding a special receptor that targets a protein called …

This phase 2 trial is testing a new CAR T-cell therapy called WZTL-002 for people with large B-cell lymphoma that has come back or not responded to standard treatment. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The study will measure …

This early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…

This early-phase study tests a new treatment for adults with certain types of blood cancer (like lymphoma) that have come back or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (CAR T-cells) desig…

This phase 2 trial is testing whether paxalisib (GDC-0084), an oral drug taken daily, can shrink or control tumors in people with recurrent or refractory primary central nervous system lymphoma (PCNSL) — a rare type of non-Hodgkin lymphoma that starts in the brain or spinal cord.…

This phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…

This study tests an experimental inhaled drug called PUL-042 in 100 people with blood cancers or who have had a stem cell transplant and have a viral lung infection. Participants receive either the drug or a placebo three times over six days. The goal is to see if PUL-042 can red…

This phase 2 trial tests whether giving patients their own personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill any remaining cancer cells. The study includes 100 people with various blood cancers like leukemia, lymphoma, and multipl…

This study tests a new type of CAR T-cell therapy that targets two proteins, CD19 and CD22, on cancer cells. It is for children and young adults aged 3 to 39 with B-cell cancers like leukemia or lymphoma that have not been cured by standard treatments. Participants receive their …

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. The drug works like a guided missile, targeting a protein (CD19) on cancer cells to deliver a toxic payload. The study aims to find…

This study tests whether a medicine called XEMBIFY, given every two weeks alongside standard care, can reduce serious bacterial infections in adults with certain blood cancers (chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma) who also have low antibody lev…

This trial is investigating whether adding an experimental drug called XNW5004 to standard chemotherapy (CHOP or CHOEP) can help people newly diagnosed with peripheral T-cell lymphoma, an aggressive type of non-Hodgkin lymphoma. The study will enroll about 176 adults aged 18 to 7…

This study tests whether a prebiotic supplement called resistant starch can improve gut microbiome diversity in people with multiple myeloma or lymphoma after an autologous stem cell transplant. Thirty participants will take either the prebiotic or a placebo for about 10 days bef…

This early-phase trial tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …

This study tests a special cord blood transplant for people with high-risk blood cancers like leukemia and lymphoma. Participants get chemotherapy and radiation before the transplant to kill cancer cells and prepare the body. After the transplant, drugs are given to prevent the n…

This early-phase trial is testing a new treatment called OriV508 for people with multiple myeloma or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. OriV508 is a type of immunotherapy that uses a virus to deliver instructions to the body to make…

This early-phase trial tests a new approach for people with certain lymphomas that have come back or not responded to treatment. Researchers take immune cells from healthy donors, modify them to recognize and attack CD30-positive cancer cells, and add a molecule (C7R) to boost th…

This early study tests a new treatment called KSVCBD for people with a type of blood cancer called B-cell non-Hodgkin's lymphoma that has come back or not responded to other treatments. KSVCBD is a special therapy that works inside the body to help immune cells attack cancer cell…

This phase 2 trial tests a personalized cell therapy called zamtocabtagene autoleucel (MB-CART2019.1) for people with B cell lymphomas that have come back or not responded to standard treatments. Participants receive their own immune cells that have been genetically modified to r…

This study tests a CAR-T cell therapy (axicabtagene ciloleucel) in 20 HIV-positive adults whose aggressive B-cell lymphoma has come back or stopped responding to standard treatment. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells. The …

This early-phase study tests a new type of immunotherapy called CD19x22 CAR T cells for teenagers and adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to attack two targets on cancer …

This study provides unlicensed cord blood units for transplant to children and adults with blood cancers, immune disorders, and other serious diseases. The goal is to see how well patients recover their white blood cells after the transplant. By making more cord blood units avail…

This early-stage trial tests whether giving radiation therapy and the antibiotic vancomycin before CAR-T cell therapy is safe and doable for people with large B-cell lymphoma. About 14 adults whose lymphoma has not responded or has come back will receive this combination. The goa…

This early-phase trial tests whether giving siltuximab before epcoritamab can prevent cytokine release syndrome (CRS), a common and sometimes severe side effect. About 20 adults with non-Hodgkin lymphoma will receive siltuximab one hour before their first epcoritamab dose. Resear…

This early-phase trial tests a new type of immune cell therapy for patients with EBV-positive Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard treatments. The researchers add a gene called C7R to the patient's own T cells to help them survive longer …

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and myeloma that have not responded to standard treatments. The drug is given as an oral capsule, either alone or combined with other cancer medicines. The goal i…

This early-phase trial is testing a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells. It is for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. The main go…

This early-phase study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are genetically modified to recognize and attack cancer cells carrying the CD30…

This phase 2 trial tests a new treatment called MB-CART2019.1 for people with a type of aggressive lymphoma (DLBCL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer c…

This study looks at whether a lower dose of radiation can safely prevent cancer from returning in people with early-stage nasal-type NK/T-cell lymphoma who have already had a complete response to chemotherapy. Participants receive 45 Gy of radiation over five weeks, targeting the…

This study tests a stem cell transplant method that removes certain immune cells (T-cells and B-cells) from the donor cells. The goal is to reduce graft-versus-host disease, a serious complication where donor cells attack the patient's body. The trial includes 20 children and you…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …

This study compares two pneumococcal vaccination strategies in 160 adults with lymphoma who have had chemotherapy. One group gets two vaccines (Prevenar 13 followed by Pneumovax 23), while the other gets a single newer vaccine (Prevenar 20). Researchers will measure immune respon…

This study tests whether giving the drug epcoritamab before and after CAR-T cell therapy can help people with relapsed or refractory large B-cell lymphoma. About 31 adults will receive epcoritamab injections, then CAR-T cells, and possibly more epcoritamab if lymphoma remains. Th…

This early-phase study tests a new treatment for people with T-cell leukemia or lymphoma that has come back. The treatment uses specially trained immune cells from a healthy donor, designed to recognize and attack cancer cells carrying a marker called CD7. The goal is to see if t…

This early-phase trial tests whether adding a drug called NT-I7 after standard CAR T-cell therapy can help the immune cells work better and last longer in people with relapsed or refractory large B-cell lymphoma. About 24 participants will receive NT-I7 after their CAR T treatmen…

This study tests whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. Participants receive the transplant as their first or second treatment. The main goal is to see how many are cancer-free one year afte…

This study tests whether giving a single dose of a targeted radiation drug (Iomab-B) before standard CAR-T cell therapy can improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 30 participants will receive the radiation followed by CAR-T ce…

This phase II trial tests different drug combinations to prevent graft-versus-host disease (GVHD) in 400 blood cancer patients receiving stem cell transplants from unrelated donors. Participants will receive either thymoglobulin or a combination of cyclophosphamide with other imm…

This study tests whether combining two oral drugs, pirtobrutinib and venetoclax, can control mantle cell lymphoma (MCL) in patients whose cancer has come back or hasn't responded to prior treatments. About 30 adults with confirmed MCL will take these pills to see how many achieve…

This early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…

This early-stage trial is testing a new oral drug called JBZ-001 in 25 adults with advanced solid tumors or certain blood cancers (like lymphoma) that have not responded to standard treatments. The drug works by blocking a protein cancer cells need to grow. The main goals are to …

This early-phase trial tests whether two drugs, ruxolitinib and abatacept, can prevent graft-versus-host disease (GVHD) and cytokine release syndrome in people receiving stem cell transplants from half-matched donors. About 41 adults with blood cancers will take these drugs aroun…

This early-phase study tests an experimental oral drug called AUR108 in adults with relapsed advanced lymphomas. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. About 40 participants will take the pill, and researchers will m…

This study tests whether adding memory immune cells (CD45RO) to a stem cell transplant can help children fight off dangerous viral and fungal infections after the procedure. The transplant uses donor stem cells that have been stripped of certain cells to prevent graft-versus-host…

This study tests an experimental oral drug called emavusertib (CA-4948), taken alone or with ibrutinib, in adults with relapsed or refractory primary central nervous system lymphoma (PCNSL). The trial has multiple parts to find the safest dose and see if the drug shrinks tumors. …

This study is testing whether a drug called polatuzumab vedotin can safely help control lymphoma after a stem cell transplant. About 20 people with B-cell or Hodgkin lymphoma who have had a relapse or not responded to prior treatment will receive the drug if their disease is stab…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…

This study tests whether a drug called sargramostim can help restore white blood cells as quickly as the standard drug (G-CSF) after a half-matched stem cell transplant for blood cancers, while possibly lowering the risk of serious infections. About 38 adults with blood cancers l…

This early-phase study tests a new drug called KSV01 in 18 adults with relapsed or refractory diffuse large B-cell lymphoma, a type of blood cancer that has not responded to standard treatments. The main goal is to check the safety of the injection and find the best dose. Partici…

This study tests a special stem cell transplant for children and adults with blood cancers like leukemia. The transplant uses stem cells that have had certain immune cells removed to lower the risk of graft-versus-host disease, a serious complication. About 70 participants will r…

This early-stage trial tests a new treatment called CLIC-2201 for people with B-cell cancers (like certain leukemias and lymphomas) that have come back or not responded to standard care. The treatment involves collecting a patient's own immune cells, modifying them to target a pr…

This early-stage trial is testing a new type of immunotherapy for people with CD30-positive blood cancers that have come back or not responded to treatment. The therapy uses a patient's own immune cells, which are collected, modified with a special antibody, and then given back t…

This study tests whether giving focused radiation to large tumors before CAR-T cell therapy can help control aggressive large B-cell lymphoma that has come back or not responded to treatment. About 27 adults with tumors at least 5 cm will receive this combination. The goal is to …

This early-phase study tests a new type of immune cell therapy (CD19 t-haNK) alone or with two other drugs (N-803 and rituximab) in up to 20 adults with relapsed or refractory non-Hodgkin lymphoma. The main goal is to check safety, and researchers will also see if the treatment s…

This study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…

This study tests whether giving cancer patients a targeted therapy that matches a specific gene change in their tumor can help shrink or control the cancer. It includes 720 adults with advanced solid tumors, multiple myeloma, or non-Hodgkin lymphoma who have no standard treatment…

This phase 2 trial is testing a new formulation of the chemotherapy drug carmustine that doesn't contain ethanol, compared to the standard version that does. Both are used as part of the BEAM conditioning regimen before an autologous stem cell transplant in adults with Hodgkin or…

This study tests a modified stem cell transplant regimen for lymphoma patients at high risk of the cancer spreading to the brain. About 45 adults who have already responded to initial treatment will receive high-dose chemotherapy with thiotepa, etoposide, cytarabine, and melphala…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…

This early-stage study tests a new treatment called GB5005 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has returned or stopped responding to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize…

This study tests a cord blood transplant in children and young adults (up to age 21) with life-threatening blood cancers or non-cancer blood disorders who do not have a matched family donor. The goal is to see if this approach lowers the risk of death from treatment one year afte…

This study tests whether the drug epcoritamab can help people with follicular lymphoma who still have signs of cancer after their first round of chemoimmunotherapy. About 35 adults with advanced-stage disease will receive epcoritamab as a second treatment. The main goal is to see…

This early-phase study tests a new drug called SB-4826 in adults with advanced solid tumors or non-Hodgkin lymphoma. The main goal is to find a safe dose and see if the drug shrinks tumors. Some participants with lymphoma will also receive the drug combined with rituximab. The st…

This early-phase study is testing a new biologic drug called PIC1 injection in 18 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tumors. It is t…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia or non-Hodgkin lymphoma. About 787 participants who completed an earlier pirtobrutinib study can join to keep receiving treatment or have follow-up visits. The main goal…

This study looks at the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL) who were already in a previous trial. About 279 participants will continue their treatment or follow-up visits. The main goal is to t…

This study tests a new way to make immune cells (called GRALE T cells) that are trained to attack cells infected with the Epstein-Barr virus (EBV), which is linked to some lymphomas. The trial includes people with Hodgkin or non-Hodgkin lymphoma, or related diseases, whose cancer…

This study tests a combination of two treatments—zanubrutinib (a targeted drug) and lisocabtagene maraleucel (a CAR T-cell therapy)—for people with Richter's syndrome, an aggressive lymphoma that can develop from chronic lymphocytic leukemia. The goal is to see if this combo can …

This early-phase trial is testing whether giving special immune cells (CMV-specific CD19-CAR T cells) along with a vaccine (CMV-MVA triplex) after a stem cell transplant can safely help prevent B-cell non-Hodgkin lymphoma from returning. About 15 people with intermediate or high-…

This phase 1/2 trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to improve treatment for people with relapsed or refractory B-cell cancers like lymphoma and leukemia. The study will enroll up to 100 adults and eva…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This phase 2 trial is testing a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—in 45 people with follicular or marginal zone lymphoma that has come back or not responded to prior treatment. The goal is to see how well the combo shrinks tumors and how safe it …

This early-phase trial tests a new drug, SGR-1505, in about 98 adults with various B-cell blood cancers (like lymphoma or leukemia) that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. Participants will receive the d…

This phase II trial tests a combination of two drugs—pembrolizumab (an immunotherapy) and ATRA (a vitamin A derivative)—in 24 adults with relapsed or refractory Hodgkin lymphoma or B-Non-Hodgkin lymphoma. The goal is to see if the combo is safe and can shrink tumors. Participants…

This study tests a personalized cell therapy called CAR T-cells for people with relapsed or hard-to-treat lymphoma or acute lymphoblastic leukemia (ALL). The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusin…

This phase 2 trial tests a personalized approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Instead of a one-size-fits-all chemotherapy and radiation regimen, doctors adjust the doses based on each patient's risk. The goal is to improve the…

This early-stage trial tests whether the experimental drug HCB101 is safe and can shrink tumors in people with advanced solid tumors or non-Hodgkin lymphoma that has come back or not responded to other treatments. About 80 adults aged 18 and older will receive the drug by IV. The…

This program offers early access to venetoclax, a targeted cancer pill, for people with certain blood cancers like leukemia or lymphoma who have no other good treatment options. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved in all…

This early-phase trial is testing a new drug called NB02 (posseltinib) in 9 adults with certain types of Non-Hodgkin lymphoma (follicular, mantle cell, or marginal zone) that have returned or not responded to at least two prior treatments. The main goals are to find a safe dose a…

This early-stage study tests a new oral drug, AXT-1003, in 78 people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug shr…

This early-phase trial tests whether infusing specially designed immune cells can prevent blood cancer from coming back after a stem cell transplant. The cells target a specific protein (HLA-DPB1*04:01) found on many cancer cells and include a 'suicide switch' to turn them off if…

This study is testing an anti-PD-1 antibody (a type of immunotherapy) alone or combined with low-dose decitabine and/or standard chemotherapy in people whose cancers have come back or not responded to treatment. The trial includes patients with several cancer types, such as lymph…

This early-stage trial tests an oral drug called AUR112 in 40 adults with relapsed advanced lymphoma. The main goals are to check safety, find the right dose, and see how the drug moves through the body. It is the first time this drug is being tested in humans.

This early-phase study tests whether a special cell therapy called T-allo10 can safely help rebuild the immune system in children and young adults (up to age 45) with blood cancers who have received a stem cell transplant. The treatment is given after the transplant to speed up r…

This study tests a new treatment for people with advanced B-cell lymphoma or leukemia that has returned or not improved after standard therapy. Researchers take a patient's own T-cells, add a special receptor (CAR) that targets the CD19 protein on cancer cells, and also add extra…

This study tests whether adding two antibody drugs (mosunetuzumab and polatuzumab) after standard CAR-T cell therapy can improve tumor shrinkage in people with aggressive non-Hodgkin lymphoma that has relapsed or not responded to prior treatments. About 22 adults will receive the…

This early-phase trial is testing a new cell therapy called LV009 for people with certain blood cancers (lymphoma and leukemia) that have come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to target cancer cells. The main goal is to c…

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

This early-stage trial tests an experimental oral drug, HSK47977, in 110 adults with relapsed or refractory Non-Hodgkin's lymphoma. The study has two parts: first, finding the safest dose, then expanding to see how well it works. Participants must have measurable tumors and adequ…

This early study tests a new treatment called LV009 injection in 10 adults whose blood cancers (certain types of lymphoma or leukemia) have returned or stopped responding to standard therapy. The main goal is to check if the treatment is safe. Participants receive the injection a…

This phase II trial is testing whether adding the JAK inhibitor ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with relapsed or refractory Hodgkin and non-Hodgkin lymphomas. The study will enroll 53 participants with specific lymphoma subtype…

This phase II trial is testing a personalized cell therapy called MB-CART19.1 in 26 adults with CD19-positive non-Hodgkin lymphoma that has relapsed or not responded to prior treatments. The therapy uses a patient's own immune cells, which are modified in the lab to recognize and…

This early-stage trial tests an oral drug called AS-1763 in about 120 adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas who have already tried at least two other treatments. The study aims to find the safest dose and check…

This study tests whether a combination of three drugs (etoposide, cytarabine, and PEG-rhG-CSF) works better than standard chemotherapy at collecting enough stem cells for a transplant in people with non-Hodgkin's lymphoma. About 99 participants who are in remission will be random…

This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago for cancers like melanoma, lymphoma, or leukemia. Researchers will track side effects, cancer return, and overall health for years. The goal is to understand the long-term safety and effec…

This study tests a new approach to collect stem cells for transplant in people with multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma. Instead of giving everyone the drug plerixafor, doctors will start with G-CSF alone and only add plerixafor if needed. The goal is to s…

This study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer …

This phase 2 trial tests whether emapalumab, a drug that blocks a protein called interferon gamma, can prevent severe cytokine release syndrome (CRS) in patients receiving CAR-T cell therapy for certain types of non-Hodgkin lymphoma. About 28 adults with relapsed or refractory la…

This early-stage study is testing a new drug called DCR-PDL1 in about 32 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and how the body processes it, not to cure the cancer. Participants will receive …

This study is for adults with two types of blood cancer—T-PLL or NHL—that have not responded to or have returned after previous treatments. Researchers are testing a new drug called APG-115, either alone or combined with another drug APG-2575, to find the safest dose and see if i…

This phase 2 study tests a stem cell transplant procedure for people with Hodgkin or non-Hodgkin lymphoma, including those with HIV. Participants receive high-dose chemotherapy followed by an infusion of their own stem cells. The goal is to see if this radiation-free approach can…

This phase 2 trial tests a two-step, lower-intensity transplant method for people with various blood cancers. The goal is to see if this gentler approach reduces the chance of dying from the transplant itself. About 63 participants will receive a combination of radiation, chemoth…

This study tests whether adding either tazemetostat or zanubrutinib to a standard two-drug therapy (tafasitamab and lenalidomide) can shrink tumors or delay cancer return in people with large B-cell lymphoma that came back or didn't respond to prior treatment. About 227 adults wh…

This early-phase trial tests a new type of stem cell transplant for children with blood cancers or solid tumors that have relapsed or not responded to standard treatment. Doctors use a half-matched donor's stem cells, specially filtered to remove certain immune cells, and give th…

This study compares immunoglobulin (given through a vein or under the skin) with antibiotics to see which better prevents severe infections in people with blood cancers like myeloma, lymphoma, or leukemia who have low antibody levels. About 900 adults will take part. The goal is …

This study compares two infection-prevention strategies in 900 people with blood cancers like myeloma and leukemia. One group gets an antibiotic (co-trimoxazole) daily, while another receives immunoglobulin infusions every few weeks. The goal is to see which approach better preve…

This study compares different ways to prevent infections in people with blood cancers like myeloma, leukemia, and lymphoma. About 900 participants will receive either daily antibiotics or immunoglobulin therapy, or a combination. The goal is to see which approach works best to ke…

This study looks at different ways to prevent serious infections in people with blood cancers like myeloma, lymphoma, and leukemia. About 900 participants will receive either antibiotics or immunoglobulin therapy to see which approach works best. The goal is to find safer and mor…

This early-stage study tests a new drug called AC676 in about 60 adults with certain blood cancers (like leukemia or lymphoma) that returned or didn't respond to prior treatments. The main goals are to find a safe dose and understand side effects. Researchers will also check how …

This program provides early access to an experimental drug called AVM0703 for people with various solid tumors and blood cancers, including hard-to-treat types like glioblastoma and metastatic breast cancer. It is available to patients in the US whose doctor requests it. So far, …

This Phase 2 trial tests a combination of the drug linperlisib plus three older drugs (cyclophosphamide, prednisone, and thalidomide) in 180 adults with non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to see how many patients achieve a complete o…

This early-phase study tests whether Darzalex Faspro can safely lower donor-specific antibodies (DSAs) in 8 adults with blood cancers or bone marrow failure who are at high risk of rejecting a stem cell transplant. The goal is to reduce DSA levels enough to allow the transplant t…

This early-stage study is testing a new biologic drug called CC312 in 44 adults with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to standard treatments. The main goals are to check safety and find the right dose. Participants receive CC31…

This early-phase trial is testing whether a second infusion of the CAR T-cell therapy Axi-Cel (called Axi-Cel-2) is safe for people with high-risk large B-cell lymphoma whose cancer came back after standard CAR T treatment. About 20 adults will receive the second infusion and be …

This study tests new diagnostic approaches for lymphoma and multicentric Castleman disease in people living with HIV who have swollen lymph nodes. Researchers will compare standard biopsies with fine needle aspiration and a new nucleic acid amplification device called TINY. The g…

This study looks at whether a wearable heart monitor and a symptom questionnaire can accurately detect autonomic dysfunction—a condition affecting heart rate and blood pressure control—in survivors of childhood leukemia and lymphoma. Researchers will compare these remote methods …

This study is testing a new radioactive tracer called 68Ga-EV203 for PET/CT scans in people with blood cancers like multiple myeloma, lymphoma, and leukemia. The goal is to see how the tracer spreads in the body, how much radiation it gives off, and whether it can find tumors bet…

This early-phase trial is testing a new radioactive imaging agent called 64Cu-LLP2A to see if it can safely and clearly show blood cancers like multiple myeloma and lymphoma on PET/CT scans. The study includes healthy volunteers and patients with these cancers, including those wh…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after a half-matched stem cell transplant. About 46 people with various blood cancers will take part…

This study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …

This phase 3 trial is testing whether adding Gamunex-C (an immune globulin) to standard care can prevent serious infections in people with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma. About 49 participants will receive Gamunex-C through an IV every 4 w…

This phase 2 trial tests a vaccine called CMV-MVA Triplex, given to stem cell donors before they donate. The goal is to boost the donor's immunity against cytomegalovirus (CMV), which can then be passed to the transplant patient. Researchers hope this will prevent CMV infection i…

This study tests an online music therapy program that combines mindfulness and music to help people recovering from stem cell transplants for blood cancers. Researchers want to see if it can improve quality of life, reduce pain, fatigue, anxiety, and depression, and possibly spee…

This study tests whether yoga and mindfulness programs can improve quality of life, reduce inflammation, and even affect gene activity in people who have survived lung, colon, or non-Hodgkin's lymphoma cancer. One hundred survivors, at least six months past treatment, will be ran…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This study tests a program called Nite2Day+ that uses mindfulness and sleep tips to help people with blood cancers sleep better and manage fatigue, stress, and pain. About 60 adults hospitalized for treatment will either get the program or standard care. The program includes a mo…

This study tests whether a 12-week program of short exercise breaks (walking, cycling, resistance bands) can improve heart health and reduce chemotherapy side effects in 24 newly diagnosed lymphoma patients. Participants will use activity trackers and get coaching to interrupt lo…

This study tests whether a Mediterranean diet and home-based exercise program can help lymphoma patients complete chemotherapy and reduce treatment-related side effects. Researchers will enroll 140 adults with untreated Hodgkin or non-Hodgkin lymphoma who need at least 6 cycles o…

This study tests a digital health program called AYA STEPS for adolescent and young adult cancer survivors. The program uses video sessions and online materials to teach skills for managing symptoms like pain, fatigue, and emotional distress, and to encourage follow-up care. Rese…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study collects blood, urine, bone marrow, and tissue samples from over 1,200 adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand cancer biology, which may lead to new methods for diagnosing or treating these diseases. No…

This observational study is recruiting 300 active-duty service members and military beneficiaries diagnosed with B-cell non-Hodgkin lymphoma. Researchers want to understand how exposure to toxins, genetic differences, and immune system problems are linked to this cancer. Particip…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This study looks at how young people (ages 6-25) with Hodgkin or non-Hodgkin lymphoma process certain medications. Researchers will give tiny, non-therapeutic doses of two common drugs (omeprazole and dextromethorphan) and measure how they are broken down in the body. The goal is…

This study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …

This study gathers blood and leftover tissue samples from 200 people newly diagnosed with aggressive non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and T-cell lymphoma. The samples are used to develop and validate blood-based tests that could monitor can…

This study is testing whether daily voice recordings can help doctors spot early signs of a brain-related side effect called ICANS in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. About 20 participants will use their smartphones to record their…

This study is a large registry that will collect medical information and biological samples from up to 10,000 adults with acute lymphoblastic leukemia (ALL) and related blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time. By gather…

This study follows people who previously received zamtocabtagene autoleucel, a CAR-T cell therapy for certain types of lymphoma. The goal is to monitor long-term health outcomes, including any new cancers, neurological issues, or autoimmune problems. By tracking participants over…

This study looks at how well vaccines for flu, COVID-19, shingles, hepatitis B, and pneumonia work in people with certain blood cancers like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas. Researchers will measure immune responses through blood samples before and af…

This study looks at whether firefighters' exposure to hazardous chemicals leads to pre-cancerous changes in their blood. Researchers will collect blood samples from 300 firefighters aged 40-49 with at least 5 years on the job. The goal is to find early markers that might predict …

This study is a large registry that will follow nearly 3,000 people with blood cancers like chronic lymphocytic leukemia and several types of lymphoma. Researchers will collect information on treatments, how the disease progresses, and patients' quality of life over time. The goa…

This study looks at whether a tailored exercise program can help older blood cancer survivors slow down the aging process. Researchers will enroll 180 people aged 50 and older who have had blood cancer. The goal is to see if participants can stick with the exercise plan and if it…

This research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…

This observational study follows 350 adults with blood cancers like lymphoma or multiple myeloma who are being treated with bispecific antibodies. Researchers will track how often infections occur, how severe they are, and what factors raise infection risk. The goal is to better …

This study is a worldwide registry that follows 5,000 adults with breast cancer, blood cancers, or those on immune checkpoint inhibitors. Researchers collect medical records, lab results, and imaging to identify who is at risk for heart problems during or after cancer treatment. …

This study collects tumor samples and medical information from people with lymphoma or related blood cancers who have a family history of these diseases. Researchers want to find genetic changes that may increase the risk of developing lymphoma. Participants provide blood or tiss…

This study tests an artificial intelligence system designed to predict when lymphoma patients might not take their oral medications as prescribed. Researchers will enroll 210 adults with non-Hodgkin lymphoma and use AI to analyze patient data, aiming to catch non-compliance early…

This study gathers basic health information from 2000 people receiving stem cell transplants for blood cancers or immune disorders. The goal is to track survival and complications to help doctors and researchers improve future treatments. Participants must be getting a standard t…

This study follows 2,000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are receiving chemotherapy or immunotherapy. Researchers will track whether using cannabis or cannabinoids helps with symptoms like pain or nausea over time. No treatme…

This study looks at memory, concentration, and language problems caused by chemotherapy in people with blood cancers like leukemia and lymphoma. Researchers will compare 120 patients to their healthy relatives using tests and questionnaires before and after treatment. The goal is…

This study interviews Spanish-speaking families of children with leukemia or lymphoma to learn about their experiences and challenges. Researchers want to understand what works well and what barriers exist in communication and access to care. The goal is to use these insights to …

This early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it shows up on PET/CT scans in people with certain blood cancers (like multiple myeloma and non-Hodgkin lymphoma) and rare immune cell tumors. About 30 participants will get the agent a…

This study aims to find the genetic causes of certain blood cancers like lymphoma, leukemia, and multiple myeloma by studying families where more than one person has the disease. Researchers will collect DNA and blood samples from up to 500 participants, including patients and th…

This study looks at tumor samples from 50 people who developed a second cancer after receiving a Bristol-Myers Squibb CAR-T cell therapy for blood cancers like lymphoma or myeloma. Researchers will test the new tumors for traces of the gene-modified cells used in the original tre…

This study looks at whether peer education and support can help more adolescents and young adults (ages 15-39) living with HIV get screened for cancer and stick with their cancer treatment. Researchers will work with 4,100 participants in Zambia to improve early diagnosis and tre…

This study looks at rare lymphomas that are hard to tell apart under the microscope—some look like Hodgkin lymphoma but lack a key marker (PAX5), making them similar to another type called anaplastic large cell lymphoma (ALCL). Researchers will analyze tissue samples from 60 adul…

This early-phase study is testing a new radioactive tracer called 64Cu-GRIP B, which is used in PET scans to detect immune cell activity. The goal is to see if this scan can predict which patients with relapsed non-Hodgkin lymphoma will have a lasting response to CAR-T cell thera…

This study follows 1,500 people with B-cell non-Hodgkin lymphoma in Italy who are treated with newer monoclonal antibodies. Researchers will track how well the cancer responds, how long patients live without the disease getting worse, and any side effects. The goal is to see how …

This study collects tumor tissue from people with Hodgkin's or non-Hodgkin's lymphoma to learn more about the cancer cells. It does not test any new treatment. Participants must already be scheduled for a routine procedure to remove lymph nodes. The goal is to better understand t…

This study creates a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will track frailty, muscle loss, and other age-related health issues to better understand this group's needs. The goal is to gather information that …

This study follows 100 people taking newer BTK inhibitor drugs (acalabrutinib or zanubrutinib) for blood cancers like leukemia or lymphoma. Researchers want to see how often these drugs cause high blood pressure or heart rhythm problems, and find early warning signs. Participants…

This study collects blood, tissue, and body fluid samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central lab for future research on diagnosis, prognosis, and immune monitoring. Participants do not receive any treatment as par…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This study is collecting medical information from 2000 people with advanced mycosis fungoides or Sézary syndrome, two rare types of skin lymphoma. The goal is to create a tool that helps doctors predict which patients are at higher or lower risk, so they can tailor treatments mor…

This study looks at families where at least two living blood relatives have a blood cancer like lymphoma, leukemia, or multiple myeloma. Researchers want to understand how genetics and environmental factors contribute to these cancers. The goal is to identify inherited risks that…

This study looks at whether a connected scale can help monitor blood cancer patients (with lymphoma or myeloma) during chemotherapy. Thirty patients will weigh themselves daily for about 7 weeks, and their data will be sent to their medical team. The goal is to see if this approa…